Clozapine has undoubtedly been the gold standard treatment for this patient
group. However, a significant proportion of patients develop intolerance to clozapine. There is limited available evidence to support the use of alternative treatment strategies. In this case report we present two diagnostically different cases, where stabilization #LY2603618 datasheet randurls[1|1|,|CHEM1|]# on clozapine was followed by discontinuation due to the development of neutropenia. These cases were subsequently managed with high doses of quetiapine, which produced a satisfactory clinical response. Case reports Our first case is a 45-year-old man diagnosed with schizoaffective disorder. Inhibitors,research,lifescience,medical He was referred to mental health services at the age of 18 and received extensive input from forensic psychiatry services due to severe disruptive behaviours, characterized by severe aggression, violence and crime whilst under the influence of manic symptoms, auditory hallucinations (which were command in nature) and delusions of persecution and grandiosity. He remained predominantly an inpatient between 1994 and Inhibitors,research,lifescience,medical 2007, mainly in medium- and high-security units. He was initiated on trifluoperazine (1994) and then lithium, fluphenazine decanoate (1995) at 200 mg/fortnightly which was above the British National Formulary (BNF) limit,
all of which produced poor responses. Clozapine was initiated in 1995 and produced a reasonable response by alleviating his delusions Inhibitors,research,lifescience,medical and controlling his behaviour. Unfortunately he developed neutropenia and Inhibitors,research,lifescience,medical clozapine was discontinued in 1996. This immediately led to major deterioration with severe aggressive behaviour warranting emergency electroconvulsive therapy (ECT). He subsequently was initiated on olanzapine, risperidone, sulpiride, quetiapine and lithium individually Inhibitors,research,lifescience,medical (up to BNF maximum limits) with poor responses. In early 2006, lithium 1000 mg/day and sulpiride 2400 mg/day combined also had minimal effects. Quetiapine was added to augment this combination at up to 800 mg/day. In 2007, he himself requested a further dose increase as he personally experienced significant improvement in his symptoms. His dose 4-Aminobutyrate aminotransferase was further increased up to 1200
mg/day under close monitoring, to which he further responded significantly. Quetiapine was well tolerated with no major concerns being reported. He was successfully discharged from the forensic setting in 2007 to a normal community placement, which marked as a significant progress for a patient who had spent nearly 12 years of his life as an inpatient in a forensic setting. To date he remains well in the community. Our second case is a 50-year-old woman diagnosed with paranoid schizophrenia. She had presented to services in 1999 and was treated with the following drug combinations: fluoxetine and trifluoperazine 20 mg; risperidone 4 mg and venlafaxine 225 mg; fluphenazine decanoate depot and risperidone 6 mg orally. All of these combinations produced a poor response.